Stock Scorecard
Stock Summary for Protagonist Therapeutics Inc (PTGX) - $40.65 as of 11/20/2024 8:37:20 PM EST
Total Score
14 out of 30
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for PTGX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PTGX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PTGX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PTGX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PTGX (56 out of 90)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 9 |
Latest News for for PTGX
Financial Details for PTGX
Company Overview |
|
|---|---|
| Ticker | PTGX |
| Company Name | Protagonist Therapeutics Inc |
| Country | USA |
| Description | Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 9/30/2024 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 40.65 |
| Price 4 Years Ago | 20.16 |
| Last Day Price Updated | 11/20/2024 8:37:20 PM EST |
| Last Day Volume | 1,047,619 |
| Average Daily Volume | 543,783 |
| 52-Week High | 48.89 |
| 52-Week Low | 16.80 |
| Last Price to 52 Week Low | 141.96% |
Valuation Measures |
|
| Trailing PE | 15.01 |
| Industry PE | 22.60 |
| Sector PE | 40.32 |
| 5-Year Average PE | -4.39 |
| Free Cash Flow Ratio | 5.17 |
| Industry Free Cash Flow Ratio | 12.03 |
| Sector Free Cash Flow Ratio | 27.97 |
| Current Ratio Most Recent Quarter | 10.70 |
| Total Cash Per Share | 7.86 |
| Book Value Per Share Most Recent Quarter | 8.94 |
| Price to Book Ratio | 4.61 |
| Industry Price to Book Ratio | 5.31 |
| Sector Price to Book Ratio | 20.88 |
| Price to Sales Ratio Twelve Trailing Months | 7.57 |
| Industry Price to Sales Ratio Twelve Trailing Months | 11.82 |
| Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 59,598,000 |
| Market Capitalization | 2,422,658,700 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 38.02% |
| Reported EPS 12 Trailing Months | 2.69 |
| Reported EPS Past Year | 2.22 |
| Reported EPS Prior Year | -1.49 |
| Net Income Twelve Trailing Months | 170,849,000 |
| Net Income Past Year | -78,955,000 |
| Net Income Prior Year | -127,393,000 |
| Quarterly Revenue Growth YOY | -100.00% |
| 5-Year Revenue Growth | 14.23% |
| Operating Margin Twelve Trailing Months | -8.87 |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 468,721,000 |
| Total Cash Past Year | 341,617,000 |
| Total Cash Prior Year | 237,355,000 |
| Net Cash Position Most Recent Quarter | 468,721,000 |
| Net Cash Position Past Year | 341,617,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 9,794,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 336,677,000 |
| Total Stockholder Equity Prior Year | 215,608,000 |
| Total Stockholder Equity Most Recent Quarter | 531,915,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 229,226,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 3.85 |
| Free Cash Flow Past Year | -70,845,000 |
| Free Cash Flow Prior Year | -108,932,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.12 |
| MACD Signal | 0.44 |
| 20-Day Bollinger Lower Band | 33.94 |
| 20-Day Bollinger Middle Band | 42.29 |
| 20-Day Bollinger Upper Band | 50.65 |
| Beta | 2.16 |
| RSI | 35.97 |
| 50-Day SMA | 33.00 |
| 150-Day SMA | 22.32 |
| 200-Day SMA | 25.17 |
System |
|
| Modified | 11/19/2024 10:48:28 AM EST |